Shenzhen Hybio Pharmaceutical Co., Ltd. (SHE: 300199) announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application (IND No.: 184763) for HY3003 Injection, a first‑in‑class, AI‑designed GLP‑1R/GIPR/GCGR triple receptor agonist for the treatment of obesity and overweight – advancing one of the first artificial intelligence‑screened peptide drugs in the metabolic disease space toward U.S. clinical trials, with preclinical data demonstrating superior weight loss to both marketed tirzepatide and investigational retatrutide at equimolar doses.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | FDA (United States) |
| Application Type | Investigational New Drug (IND) – accepted for review |
| IND Number | 184763 |
| Product | HY3003 Injection (weekly subcutaneous) |
| Sponsor | Hybio Pharmaceutical Co., Ltd. |
| Acceptance Date | 5 October 2026 |
| Indication | Long‑term weight management in adults with BMI ≥28 kg/m² (obesity) or ≥24 kg/m² (overweight) with ≥1 weight‑related comorbidity |
| 30‑Day Review | Clinical trials may commence if FDA does not issue a clinical hold within 30 days of acceptance |
| Drug Discovery Platform | AI peptide chip technology (AI多肽芯片技术) |
Drug Profile & Mechanism of Action
- Molecule: HY3003 – a triple receptor agonist targeting GLP‑1R (glucagon‑like peptide‑1 receptor), GIPR (glucose‑dependent insulinotropic polypeptide receptor), and GCGR (glucagon receptor), discovered through Hybio’s proprietary AI peptide chip screening technology
- Triple‑Target Rationale:
- GLP‑1R agonism: Appetite suppression, slowed gastric emptying, improved insulin secretion – the validated backbone of modern obesity pharmacotherapy
- GIPR agonism: Synergistic enhancement of incretin effect, improved lipid metabolism, and potential reduction in GLP‑1‑associated nausea
- GCGR agonism: Increased energy expenditure, enhanced hepatic lipid metabolism, and direct reduction of liver fat – a mechanism uniquely positioned to address MASH/NASH and metabolic syndrome beyond weight loss alone
- AI Drug Discovery: HY3003 was identified using AI‑driven peptide chip technology, representing the application of machine learning and computational biology to optimize peptide sequence, receptor selectivity, and pharmacokinetic properties – a next‑generation drug discovery approach that accelerates lead optimization and reduces development timelines
- Multi‑Format Development Strategy: Hybio is pursuing a parallel multi‑formulation development approach:
- HY3003 Injection (weekly subcutaneous; pre‑filled syringe + auto‑injector pen) – current IND filing
- HY3003 Sustained‑Release Injection (monthly formulation) – in development
- HY3003 Tablets (once‑daily oral) – in development
- Target Indications: Weight management (obesity/overweight), type 2 diabetes, and metabolic dysfunction‑associated steatohepatitis (MASH)
Preclinical Evidence – DIO Mouse Model
| Endpoint | HY3003 | Tirzepatide (Dual GLP‑1/GIP) | Retatrutide (Triple GLP‑1/GIP/GCG) |
|---|---|---|---|
| Weight Loss (Equimolar Dose) | Superior | Baseline comparison | Baseline comparison |
| Blood Glucose Reduction | Favorable pharmacodynamic profile | – | – |
| Fat Reduction | Favorable pharmacodynamic profile | – | – |
| Hepatic Steatosis Improvement | Favorable pharmacodynamic profile | – | – |
| Specific Numeric Data | Not disclosed in press release | – | – |
Preclinical pharmacodynamic studies in diet‑induced obese (DIO) mice – the standard translational model for obesity pharmacotherapy – demonstrated that HY3003 achieved superior weight loss at equimolar doses compared to both tirzepatide (the marketed dual GLP‑1/GIP agonist, Zepbound/Mounjaro) and retatrutide (Eli Lilly’s investigational triple agonist in Phase III). The drug also exhibited favorable effects on glycemic control, fat mass reduction, and hepatic steatosis improvement – supporting its potential as a best‑in‑class triple agonist candidate.
Clinical Context – Obesity Therapeutics Landscape
| Drug | Targets | Dosing | Developer | Status |
|---|---|---|---|---|
| Semaglutide (Wegovy) | GLP‑1 | Weekly SC | Novo Nordisk | Marketed |
| Tirzepatide (Zepbound) | GLP‑1 + GIP | Weekly SC | Eli Lilly | Marketed |
| Retatrutide | GLP‑1 + GIP + GCG | Weekly SC | Eli Lilly | Phase III |
| Survodutide | GLP‑1 + GCG | Weekly SC | Boehringer Ingelheim | Phase III |
| HY3003 | GLP‑1 + GIP + GCG | Weekly SC (monthly + oral in pipeline) | Hybio Pharmaceutical | IND accepted (U.S.) |
The evolution of obesity pharmacotherapy is progressing from single‑target (GLP‑1) to dual‑target (GLP‑1/GIP) to triple‑target (GLP‑1/GIP/GCG) agonists, with each incremental target addition delivering greater weight loss and broader metabolic benefits. The glucagon receptor component specifically addresses energy expenditure and liver fat reduction – mechanisms not adequately captured by incretin‑only approaches, making triple agonists particularly attractive for patients with concomitant obesity, diabetes, and MASH.
Market Impact & Outlook
- Triple Agonist Competitive Race: HY3003 enters the triple receptor agonist space currently led by Eli Lilly’s retatrutide (Phase III), which reported up to 24% weight loss in Phase II data. HY3003’s preclinical demonstration of superior efficacy at equimolar doses positions it as a potential challenger, though clinical confirmation in human trials will be essential.
- AI Drug Discovery Validation: HY3003 represents one of the first AI‑designed peptide drugs to advance to FDA IND stage in the obesity/metabolic disease space, validating Hybio’s AI peptide chip platform as a viable drug discovery engine. If HY3003 succeeds clinically, it could establish a template for AI‑driven peptide optimization across multiple therapeutic areas.
- Multi‑Format Strategic Optionality: The parallel development of weekly injection, monthly sustained‑release injection, and daily oral tablet provides Hybio with three potential commercial entry points across different patient segments and administration preferences – a comprehensive platform strategy that mirrors Novo Nordisk’s semaglutide franchise model (injectable Wegovy + oral Rybelsus).
- Global Obesity Market Scale: The global anti‑obesity drug market is projected to exceed US$100 billion by 2030, driven by the clinical and commercial success of GLP‑1‑based therapies. A triple agonist with differentiated discovery methodology and multi‑format delivery options could capture meaningful share in this rapidly expanding market.
- MASH Indication Upside: The glucagon receptor component of HY3003 provides a direct mechanistic rationale for MASH treatment (hepatic fat reduction, energy expenditure), creating potential for a multi‑indication development program spanning obesity, T2D, and MASH – significantly expanding the addressable market.
- Hybio Pharmaceutical’s Innovation Pivot: This IND acceptance marks a significant milestone in Hybio’s transformation from a generic peptide manufacturer (insulin analogues, GLP‑1 peptides) into an innovative drug developer with proprietary AI‑driven discovery capabilities and a first‑in‑class clinical asset.
- Regulatory Timeline: Under FDA rules, Hybio may initiate clinical trials 30 days after IND acceptance unless the FDA issues a clinical hold. Phase I study design, enrollment timeline, and potential partnership discussions Not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the clinical development, regulatory trajectory, and commercial potential of HY3003 in obesity, type 2 diabetes, and MASH. FDA IND acceptance does not constitute approval to proceed with clinical trials; a clinical hold may be issued within the 30‑day review period. Actual outcomes may differ due to risks including clinical trial performance, safety findings in humans, regulatory decisions, competitive dynamics, and the inherent uncertainties of translating preclinical data into approved therapeutics.-Fineline Info & Tech
